{
  "symbol": "BEIGF",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2152,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.288
  },
  "top_positive": [
    {
      "sent": "These forward\u2011looking statements include, among other things, statements about: \u2022 our ability to successfully commercialize our approved medicines and to obtain approvals in additional indications and territories for our medicines; \u2022 our ability to successfully develop and commercialize our in-licensed medicines and drug candidates and any other medicines and drug candidates we may in-license ; \u2022 our ability to further develop sales and marketing capabilities and launch and commercialize new medicines, if approved ; \u2022 our ability to maintain and expand regulatory approvals for our medicines and drug candidates, if approved ; \u2022 the pricing and reimbursement of our medicines and drug candidates, if approved; \u2022 the initiation, timing, progress and results of our preclinical studies and clinical trials and our research and development programs; \u2022 our ability to advance our drug candidates into, and successfully complete, clinical trials and obtain regulatory approvals; \u2022 our reliance on the success of our clinical stage drug candidates; \u2022 our plans, expected milestones and the timing or likelihood of regulatory filings and approvals; \u2022 the implementation of our business model, strategic plans for our business, medicines, drug candidates and technology; \u2022 the scope of protection we (or our licensors) are able to establish and maintain for intellectual property rights covering our medicines, drug candidates and technology; \u2022 our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; \u2022 costs associated with enforcing or defending against intellectual property infringement, misappropriation or violation, product liability and other claims; \u2022 the regulatory environment and regulatory developments in the United States, China, the United Kingdom, Switzerland, the European Union (\"EU\") and other jurisdictions in which we operate; \u2022 the accuracy of our estimates regarding expenses, revenues, capital requirements and our need for additional financing; \u2022 the potential benefits of strategic collaboration and licensing agreements and our ability to enter into and maintain strategic arrangements; \u2022 our plans and expectations to build significant technical operations and independent production capabilities for small molecule medicines and large molecule biologics to support the global demand for both commercial and clinical supply; \u2022 our reliance on third parties to conduct drug development, manufacturing and other services; \u2022 our ability to manufacture and supply, or have manufactured and supplied, drug candidates for clinical development and medicines for commercial sale; \u2022 the rate and degree of market access and acceptance of our medicines and drug candidates, if approved; 1 Table of Contents \u2022 developments relating to our competitors and our industry, including competing therapies; \u2022 the size of the potential markets for our medicines and drug candidates and our ability to serve those markets; \u2022 our ability to effectively manage our growth; \u2022 our ability to attract and retain qualified employees and key personnel; \u2022 statements regarding future revenue, hiring plans, key milestones, expenses, capital expenditures, capital requirements and share performance; \u2022 the future trading price of our American Depositary Shares (\"ADS\") listed on NASDAQ, our ordinary shares listed on HKEx, and our ordinary shares issued to permitted investors in China and listed and traded on the STAR in Renminbi (\"RMB Shares\"), as well as the impact of securities analysts\u2019 reports on these prices; and \u2022 the impact of the COVID-19 pandemic on our clinical development, regulatory, commercial, manufacturing, and other operations.",
      "score": 0.998
    },
    {
      "sent": "These forward\u2011looking statements include, among other things, statements about: \u2022 our ability to successfully commercialize our approved medicines and to obtain approvals in additional indications and territories for our medicines; \u2022 our ability to successfully develop and commercialize our in-licensed medicines and drug candidates and any other medicines and drug candidates we may in-license ; \u2022 our ability to further develop sales and marketing capabilities and launch and commercialize new medicines, if approved ; \u2022 our ability to maintain and expand regulatory approvals for our medicines and drug candidates, if approved ; \u2022 the pricing and reimbursement of our medicines and drug candidates, if approved; \u2022 the initiation, timing, progress and results of our preclinical studies and clinical trials and our research and development programs; \u2022 our ability to advance our drug candidates into, and successfully complete, clinical trials and obtain regulatory approvals; \u2022 our reliance on the success of our clinical stage drug candidates; \u2022 our plans, expected milestones and the timing or likelihood of regulatory filings and approvals; \u2022 the implementation of our business model, strategic plans for our business, medicines, drug candidates and technology; \u2022 the scope of protection we (or our licensors) are able to establish and maintain for intellectual property rights covering our medicines, drug candidates and technology; \u2022 our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; \u2022 costs associated with enforcing or defending against intellectual property infringement, misappropriation or violation, product liability and other claims; \u2022 the regulatory environment and regulatory developments in the United States, China, the United Kingdom, Switzerland, the European Union (\"EU\") and other jurisdictions in which we operate; \u2022 the accuracy of our estimates regarding expenses, revenues, capital requirements and our need for additional financing; \u2022 the potential benefits of strategic collaboration and licensing agreements and our ability to enter into and maintain strategic arrangements; \u2022 our plans and expectations to build significant technical operations and independent production capabilities for small molecule medicines and large molecule biologics to support the global demand for both commercial and clinical supply; \u2022 our reliance on third parties to conduct drug development, manufacturing and other services; \u2022 our ability to manufacture and supply, or have manufactured and supplied, drug candidates for clinical development and medicines for commercial sale; \u2022 the rate and degree of market access and acceptance of our medicines and drug candidates, if approved; 1 Table of Contents \u2022 developments relating to our competitors and our industry, including competing therapies; \u2022 the size of the potential markets for our medicines and drug candidates and our ability to serve those markets; \u2022 our ability to effectively manage our growth; \u2022 our ability to attract and retain qualified employees and key personnel; \u2022 statements regarding future revenue, hiring plans, key milestones, expenses, capital expenditures, capital requirements and share performance; \u2022 the future trading price of our American Depositary Shares (\"ADS\") listed on NASDAQ, our ordinary shares listed on HKEx, and our ordinary shares issued to permitted investors in China and listed and traded on the STAR in Renminbi (\"RMB Shares\"), as well as the impact of securities analysts\u2019 reports on these prices; and \u2022 the impact of the COVID-19 pandemic on our clinical development, regulatory, commercial, manufacturing, and other operations.",
      "score": 0.998
    },
    {
      "sent": "These forward\u2011looking statements include, among other things, statements about: \u2022 our ability to successfully commercialize our approved medicines and to obtain approvals in additional indications and territories for our medicines; \u2022 our ability to successfully develop and commercialize our in-licensed medicines and drug candidates and any other medicines and drug candidates we may in-license ; \u2022 our ability to further develop sales and marketing capabilities and launch and commercialize new medicines, if approved ; \u2022 our ability to maintain and expand regulatory approvals for our medicines and drug candidates, if approved ; \u2022 the pricing and reimbursement of our medicines and drug candidates, if approved; \u2022 the initiation, timing, progress and results of our preclinical studies and clinical trials and our research and development programs; \u2022 our ability to advance our drug candidates into, and successfully complete, clinical trials and obtain regulatory approvals; \u2022 our reliance on the success of our clinical stage drug candidates; \u2022 our plans, expected milestones and the timing or likelihood of regulatory filings and approvals; \u2022 the implementation of our business model, strategic plans for our business, medicines, drug candidates and technology; \u2022 the scope of protection we (or our licensors) are able to establish and maintain for intellectual property rights covering our medicines, drug candidates and technology; \u2022 our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; \u2022 costs associated with enforcing or defending against intellectual property infringement, misappropriation or violation, product liability and other claims; \u2022 the regulatory environment and regulatory developments in the United States, China, the United Kingdom, Switzerland, the European Union (\"EU\") and other jurisdictions in which we operate; \u2022 the accuracy of our estimates regarding expenses, revenues, capital requirements and our need for additional financing; \u2022 the potential benefits of strategic collaboration and licensing agreements and our ability to enter into and maintain strategic arrangements; \u2022 our plans and expectations to build significant technical operations and independent production capabilities for small molecule medicines and large molecule biologics to support the global demand for both commercial and clinical supply; \u2022 our reliance on third parties to conduct drug development, manufacturing and other services; \u2022 our ability to manufacture and supply, or have manufactured and supplied, drug candidates for clinical development and medicines for commercial sale; \u2022 the rate and degree of market access and acceptance of our medicines and drug candidates, if approved; 1 Table of Contents \u2022 developments relating to our competitors and our industry, including competing therapies; \u2022 the size of the potential markets for our medicines and drug candidates and our ability to serve those markets; \u2022 our ability to effectively manage our growth; \u2022 our ability to attract and retain qualified employees and key personnel; \u2022 statements regarding future revenue, hiring plans, key milestones, expenses, capital expenditures, capital requirements and share performance; \u2022 the future trading price of our American Depositary Shares (\"ADS\") listed on NASDAQ, our ordinary shares listed on HKEx, and our ordinary shares issued to permitted investors in China and listed and traded on the STAR in Renminbi (\"RMB Shares\"), as well as the impact of securities analysts\u2019 reports on these prices; and \u2022 the impact of the COVID-19 pandemic on our clinical development, regulatory, commercial, manufacturing, and other operations.",
      "score": 0.998
    }
  ],
  "top_negative": [
    {
      "sent": "In any event, the receipt of regulatory approval does not assure the success of our commercialization efforts for our medicines\nur inability to reach agreements on acceptable terms with CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly; manufacturing issues, including problems with manufacturing, supply quality, compliance with GMP, or obtaining sufficient quantities of a drug candidate for use in a clinical trial or for commercialization; clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs; the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate; our third-party contractors, including clinical investigators, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a finding of a lack of clinical response or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks; regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical research or not rely on the results of clinical research for various reasons, including noncompliance with regulatory requirements; the cost of clinical trials of our drug candidates may be greater than we anticipate; and the supply or quality of our medicines and drug candidates, companion diagnostics or other materials necessary to conduct clinical trials of our drug candidates or commercialization of our medicines may be insufficient or inadequate.",
      "score": -0.9757
    },
    {
      "sent": "Mirati is also conducting its own clinical studies with sitravatinib, including the Phas3 SAPPHIRE trial in non Sq NSCLC; \u2020\u2020 ZW25; 1 By MapKure, a JV with SpringWorks Abbreviations: AML = acute myelogenous leukemia; BC = breast cancer; BTC = biliary tract cancers; CRC = colorectal cancer; GC = gastric cancer; GEA = gastroesophageal adenocarcinoma; GEJC = gastroesophaegeal junction cancer; HCC = hepatocellular carcinoma; MDS = myelodysplastic syndromes; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer Our Commercial- and Clinical-Stage Drug Candidates A description of our commercial- and clinical-stage drug candidates and clinical data from selected clinical trials is set forth below.",
      "score": -0.9728
    },
    {
      "sent": "Mirati is also conducting its own clinical studies with sitravatinib, including the Phas3 SAPPHIRE trial in non Sq NSCLC; \u2020\u2020 ZW25; 1 By MapKure, a JV with SpringWorks Abbreviations: AML = acute myelogenous leukemia; BC = breast cancer; BTC = biliary tract cancers; CRC = colorectal cancer; GC = gastric cancer; GEA = gastroesophageal adenocarcinoma; GEJC = gastroesophaegeal junction cancer; HCC = hepatocellular carcinoma; MDS = myelodysplastic syndromes; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer Our Commercial- and Clinical-Stage Drug Candidates A description of our commercial- and clinical-stage drug candidates and clinical data from selected clinical trials is set forth below.",
      "score": -0.9728
    }
  ],
  "forward_snippets": [
    "We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, and operating results.",
    "While we believe these industry publications and third-party research, surveys and studies are reliable, you are cautioned not to give undue weight to this information.",
    "We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, and operating results.",
    "While we believe these industry publications and third-party research, surveys and studies are reliable, you are cautioned not to give undue weight to this information.",
    "\u2022 If we or any third parties with which we may collaborate to market and sell our medicines are unable to achieve and maintain coverage and adequate levels of reim\ntrends that we believe may affect our business, financial condition, and operating results."
  ]
}